Today: 11 June 2026
Salesforce stock rises as RBC lifts price target, AI demand back in focus
5 January 2026
1 min read

Salesforce stock rises as RBC lifts price target, AI demand back in focus

New York, Jan 5, 2026, 11:23 ET — Regular session

  • Salesforce shares rose about 1.4% in late morning trade.
  • RBC Capital Markets raised its price target while keeping a neutral rating.
  • Investors are watching Friday’s U.S. jobs report and Salesforce’s next earnings date.

Salesforce shares rose about 1.4% to $257.07 on Monday, tracking a firmer tone in U.S. equities after RBC Capital Markets raised its price target on the enterprise software maker.

The call matters because investors are starting the year still debating whether “enterprise AI” spending is translating into recurring revenue, not just pilot projects. Salesforce has positioned its newer AI agent products as a growth driver, and analyst target changes can shape near-term positioning in a stock that is widely held and sits in the Dow.

It also lands as traders reassess risk appetite after a choppy turn for big-cap technology late last week. The question for software names like Salesforce is whether budgets are stabilizing as boards demand clearer returns on AI spending.

U.S. stocks were higher, with the Dow at a record and the S&P 500 and Nasdaq also up in late morning trading, Reuters reported, as energy and financial shares led gains following a U.S. strike in Venezuela and investors looked ahead to key economic data.

RBC Capital analyst Rishi Jaluria raised Salesforce’s price target to $290 from $250 and kept a “Sector Perform” rating, according to a report carried by TipRanks. “2026 is likely to be a year when AI tailwinds become more evident,” Jaluria wrote, adding that enterprise spending appears to be stabilizing in select areas. TipRanks

Salesforce last raised its fiscal 2026 revenue and adjusted profit forecasts in early December, citing stronger demand for its AI agent platform and related data products. The company said Agentforce and Data 360 reached nearly $1.4 billion in annual recurring revenue (ARR), a subscription run-rate metric, up 114% year-on-year.

RBC’s new target implies roughly 13% upside from Monday’s trading levels, but the unchanged rating signals the firm is not calling for a broad re-rating in the near term. For many investors, the next leg hinges on evidence that AI “agents” are converting from experiments into paid deployments that lift bookings and renewals.

But the downside case is straightforward: enterprise customers can stretch decision cycles, and early AI deployments may not scale fast enough to offset price pressure and intensifying competition across cloud software. Any renewed volatility in rates-sensitive growth stocks would also test sentiment, even if company fundamentals hold.

Macro is also in the frame this week. The U.S. Labor Department is scheduled to publish the December employment report at 8:30 a.m. ET on Friday, Jan. 9, a release that can swing expectations for Federal Reserve policy and valuations for long-duration tech shares.

For Salesforce specifically, the next focal point is its upcoming results, which Public.com lists for Feb. 25, when investors will scrutinize guidance, AI product traction and margins.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
BAE Systems shares jump nearly 5% as Venezuela shock lifts European defense stocks
Previous Story

BAE Systems shares jump nearly 5% as Venezuela shock lifts European defense stocks

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR
Next Story

NuScale Power stock jumps 16% as House sets ‘New Nuclear Era’ hearing — what’s next for SMR

Go toTop